首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1085750

GM1神经节苷脂贮积病治疗的全球市场:各产品类型，各疾病类型，各地区 - 规模，占有率，展望，机会分析(2022年～2028年)

GM1 Gangliosidosis Treatment Market, by Product Type, by Disease Type, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月01日 | 出版商:

Coherent Market Insights | 英文 101 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球GM1神经节苷脂贮积病治疗市场上，主要企业为了提高存在感，着重策略性协定。

本报告提供全球GM1神经节苷脂贮积病治疗市场相关调查分析，推动市场要素与阻碍因素，市场机会，COVID-19影响，各产品类型、疾病类型、地区的市场分析，竞争情形等资讯。

GM1 gangliosidosis is a progressive neurological genetic disorder mainly caused by the absence of a vital enzyme known as beta-galactosidase (GLB1). Without GLB1, a fatty substance called GM1 gangliosidosis accumulates in cells, and nerve cells of the brain. GM1 gangliosidosis is one of the 50 genetically inherited disorders known as lysosomal storage diseases. Currently, there is no treatment or cure for treatment of GM1 gangliosidosis.

Market Dynamics

Key players are focusing on strategic agreements in order to expand their presence in the market. For instance, in May 2017, Lysogene entered a strategic manufacturing agreement with Brammer Bio, a viral gene and cell therapy manufacturer. The agreement is expected to help Brammer Bio manufacture LYS-GM101, an AAVrh10- based gene therapy for the treatment of GM1 gangliosidosis.

Key features of the study:

This report studies the current scenario as well as the future potential of the global GM1 gangliosidosis market. The market for GM1 gangliosidosis is segmented on the basis of product type, disease type, and region.
This report provides in-depth analysis of the global GM1 gangliosidosis market, and provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
It profiles leading players in the global GM1 gangliosidosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future market expansion and marketing tactics
The global GM1 gangliosidosis market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through various strategy matrices used in analyzing the global GM1 gangliosidosis market

Detailed Segmentation:

Global GM1 Gangliosidosis Treatment Market, By Product Type :
- LYS-GM101
- PBGM01
- AXO-AAV-GM1
Global GM1 Gangliosidosis Treatment Market, By Disease Type :
- Type 1 GM1 Gangliosidosis
- Type 2 GM1 Gangliosidosis
- Type 3 GM1 Gangliosidosis
Global GM1 Gangliosidosis Treatment Market, By Region:
- North America
  - By Product Type:
  - LYS-GM101
  - PBGM01
  - AXO-AAV-GM1
  - By Disease Type :
  - Type 1 GM1 Gangliosidosis
  - Type 2 GM1 Gangliosidosis
  - Type 3 GM1 Gangliosidosis
  - By Country:
  - U.S.
  - Canada
- Europe
  - By Product Type:
  - LYS-GM101
  - PBGM01
  - AXO-AAV-GM1
  - By Disease Type :
  - Type 1 GM1 Gangliosidosis
  - Type 2 GM1 Gangliosidosis
  - Type 3 GM1 Gangliosidosis
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Rest of World
  - By Product Type:
  - LYS-GM101
  - PBGM01
  - AXO-AAV-GM1
  - By Disease Type :
  - Type 1 GM1 Gangliosidosis
  - Type 2 GM1 Gangliosidosis
  - Type 3 GM1 Gangliosidosis
  - By Region:
  - Latin America
  - Asia Pacific
  - Middle East
  - Africa.
Company Profiles.
- Axovant Gene Therapies Ltd. *
  - Company Overview
  - Material Portfolio
  - Financial Performance
  - Key Highlights
  - Market Strategies
- Passage Bio
- Lyosgene

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Product Type
Market Snapshot, By Disease Type
Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Pipeline Analysis
Regulatory Scenario
Key Development
Epidemiology
Primary Research Insights
Patient Insights
Physician Insights
Manufacturer Insights

4. Global GM1 Glangliosidosis Treatment Market - Impact of COVID-19 Pandemic

Economic Impact
COVID-19 Epidemiology
Impact of COVID-19 on Ongoing Clinical Trials

5. Global GM1 Glangliosidosis Treatment Market, By Product Type, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- LYS-GM101
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- PBGM01
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- AXO-AAV-GM1
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global GM1 Glangliosidosis Treatment Market, By Disease Type, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- Type 1 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Type 2 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Type 3 GM1 Gangliosidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global GM1 Glangliosidosis Treatment Market, By Region, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, By Country, 2022 and 2028 (%)
Y-o-Y Growth Analysis, For Countries, 2017 - 2028
North America
Introduction
Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
Europe
Introduction
Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Rest of World
Introduction
Market Size and Forecast, By Product Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Disease Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Latin America
- Asia Pacific
- Middle East
- Africa.

8. Competitive Landscape

Company Profiles
Axovant Gene Therapies Ltd.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Passage Bio
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Lysogene
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies

02-2729-4219

+886-2-2729-4219

License/价格

GM1神经节苷脂贮积病治疗的全球市场:各产品类型，各疾病类型，各地区 - 规模，占有率，展望，机会分析(2022年～2028年)

GM1 Gangliosidosis Treatment Market, by Product Type, by Disease Type, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章调查目的、前提条件

第2章市场范围

第3章市场动态、法规、趋势分析

第4章全球GM1神经节苷脂贮积病治疗市场:COVID-19流行的影响

第5章全球GM1神经节苷脂贮积病治疗市场:各产品类型(2017年～2028年)

第6章全球GM1神经节苷脂贮积病治疗市场:各疾病类型(2017年～2028年)

第7章全球GM1神经节苷脂贮积病治疗市场:各地区(2017年～2028年)

第8章竞争情形